

Press Release

Nicox Provides First Half 2022 Business Update and Financial Results

- Topline results from first pivotal Phase 3 glaucoma clinical trial on NCX 470, Mont Blanc, due in November 2022
- Net revenue €1.4 million for H1 2022; cash of €31.6 million on June 30, 2022

September 16, 2022 – release at 7:30 am CET Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided business and financial results for Nicox SA and its subsidiaries (the "Nicox Group") for the first half of 2022.

"I joined Nicox because I saw the potential for NCX 470 to be the first true successor to the first prostaglandin analog approved for the lowering of intraocular pressure, Xalatan, which I launched while at Pharmacia. Substantial progress has been made this year with completion of enrolment in the pivotal Phase 3 Mont Blanc trial for our lead asset, NCX 470, targeting glaucoma, and we are just weeks away from the results of the first of the two Phase 3 trials. These data, due in November, could provide the cornerstone for building the future of the company," said Andreas Segerros, Chief Executive Officer of Nicox. "NCX 470 has already demonstrated a statistically significant improvement over the standard of care for intraocular pressure lowering, latanoprost, in a robust Phase 2 clinical trial. We have also demonstrated beneficial effects in an in vivo model of damage to the optic nerve head and retina. We believe the ongoing Phase 3 program will demonstrate the potential for NCX 470 as a best-in-class glaucoma treatment, addressing a major need in this nearly \$6 billion worldwide market, and we are excited to see these results."

Andreas Segerros continued, "In my first few months here I have discovered a very strong ophthalmologyfocussed R&D team, which we have since rounded out with excellent new hires, supported by an experienced, competent, corporate, finance and legal organisation. I am delighted to have joined Nicox at such an important time in the company's history. After reviewing the portfolio, I believe we are well positioned to build upon the strength of the NCX 470 program by potentially advancing our novel nitric oxide-donating phosphodiesterase-5 inhibitor, NCX 1728, and through the opportunistic addition of other programs to the development pipeline."

"The NCX 470 data presented to date has the potential to significantly impact the glaucoma treatment paradigm." said Dr Robert Weinreb, Distinguished Professor and Chair of Ophthalmology at the University of California, San Diego, and member of Nicox's Glaucoma Clinical Advisory Board".

First Half 2022 Business Update

- Andreas Segerros joined Nicox as Chief Executive Officer on June 1, 2022. He brings significant pharma and venture capital expertise, including in ophthalmology, specifically as Global Head of Pharmaceutical Ophthalmology at Pharmacia, where he launched XALATAN[®] (latanoprost), making it the industry's first billion-dollar ophthalmic drug.
- With the appointment of Andreas Segerros as Chief Executive Officer, the role was separated from that of Chairman. Jean-Francois Labbé, Board member and Chairman of the Audit Committee, was appointed as Chairman of the Board of Directors of Nicox SA, effective July 28, 2022.



- NCX 470, Nicox's lead clinical product candidate, is a novel, potentially best-in-class, nitric oxide (NO)-donating prostaglandin analog eye drop currently in a Phase 3 program for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Topline results from the first Phase 3 clinical trial, Mont Blanc, are due in November. Positive results of the Dolomites Phase 2 clinical trial on NCX 470 were reported in October 2019.
- Patient enrollment is continuing in both the United States (U.S.) and China in the ongoing Denali Phase 3 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension. The Denali trial is being jointly conducted and equally financed with our Chinese partner, Ocumension Therapeutics. Based on the current recruitment rates, the Company expects topline results after 2024. The timeline has been impacted by COVID-19, specifically the lockdown in China, and longer-term effects on the wider glaucoma clinical trial environment.
- NCX 4251 is a novel, patented, ophthalmic suspension of fluticasone propionate nanocrystals for dry eye disease. The Company is currently looking for partnerships outside of China to advance development of this program. NCX 4251 is exclusively licensed to Ocumension Therapeutics in the Chinese market.
- **VYZULTA**[®] (latanoprostene bunod ophthalmic solution), 0.024%, is now approved in 18 markets, including approval in Lebanon in the second quarter of 2022. Following a launch in Thailand in the second quarter of 2022, it is now commercialized in 8 territories, and a launch in Brazil is expected in the fourth quarter of this year. VYZULTA is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.

First Half 2022 Financial Results

As of June 30, 2022, the Nicox Group had cash and cash equivalents of €31.6 million, as compared with €35.1 million at March 31, 2022 and €42.0 million at December 31, 2021. The Company estimates that it is financed into Q4 2023, based on the development of NCX 470 alone, and assuming the extension¹ of the interest only period of the existing Kreos debt.

As of June 30, 2022, the Nicox Group had financial debt of ≤ 20.6 million consisting of ≤ 18.6 million in the form of a bond financing agreement with Kreos Capital signed in January 2019 and a ≤ 2.0 million credit agreement guaranteed by the French State in August 2020 in the context of the COVID-19 pandemic.

Net revenue² for the first half of 2022 was \in 1.4 million (including \in 1.3 million in royalty revenue) versus \in 1.3 million (including \in 1.2 million in royalty revenue) for the first half of 2021.

Operating expenses for the first half of 2022 were €12.7 million compared to €13.4 million for the first half of 2021.

The Nicox Group recorded a net loss of \in 17.0 million for the six months ended June 30, 2022, compared to a net loss of \in 11.7 million for the same period in 2021. The H1 2022 net loss includes \in 11.1 million of non-recurring, non-cash items due to the decision to seek a partner to pursue the development of NCX 4251 in the U.S.

Only the figure related to the cash position of the Nicox Group as of December 31, 2021 is audited; all other figures in this press release are non-audited.

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also conducting research on NCX

¹ Nicox has the option to extend the interest-only period of the existing Kreos debt by 6 months if the Mont Blanc trial on NCX 470 meets its primary endpoint of non-inferiority to latanoprost

² Net revenue consists of revenue from collaborations less royalty payments which corresponds to Net profit in the consolidated statements of profit or loss



1728, a nitric oxide-donating phosphodiesterase 5 inhibitor, in intraocular pressure lowering and retinal conditions. NCX 4251, a novel, patented, ophthalmic suspension fluticasone propionate nanocrystals for topical ocular application for dry eye disease, is being developed by Ocumension Therapeutics in China under an exclusive license agreement and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC (a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd.), in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co Edison Investment Research H.C. Wainwright & Co Kepler Cheuvreux Dylan Van Haaften Pooya Hemami Yi Chen Arsene Guekam Paris, France London, UK New York, U.S. Paris, France



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Nicox

Gavin Spencer Executive Vice President, Chief Business Officer & Head of Corporate Development T +33 (0)4 97 24 53 00 communications@nicox.com Investors & Media United States & Europe LifeSci Advisors, LLC Sandya von der Weid T +41 78 680 05 38 svonderweid@lifesciadvisors.com

Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 3rd chapter of the '*Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2021*' filed with the French Autorité des Marchés Financiers (AMF) on April 29, 2022 which is available on Nicox's website (<u>www.nicox.com</u>)

Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99



NICOX SA INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	6 Months period	6 Months period ending June 30,	
	2022	2021	
	(in thousands of € exc	cept for per share data	
Revenues from collaborations	2,322	2,043	
Royalty payments	(892)	(721)	
Net Profit from collaborations	1,430	1,322	
Research and development expenditures	(7,778)	(10,000)	
Administrative expenses	(3,724)	(3,263)	
Other income	371	466	
Other expenses	(1,190)	(90)	
Operating loss before amortization of intangible assets	(10,891)	(11,565)	
Amortization of intangible assets	-	(587)	
Impairment of intangible assets ⁽¹⁾	(10,472)	-	
Operating loss	(21,363)	(12,152)	
Finance income	3,915	1,451	
Finance expense	(1,237)	(1,036)	
Net financial income/(expense)	2,678	415	
Loss before tax	(18,685)	(11,737)	
Income tax (expense) / benefit	1,679	24	
Net loss for the period	(17,006)	(11,713)	

(1) Non-cash adjustment on NCX4251 estimated fair value due to the Group decision to seek for a partner to pursue the development in USA.



NICOX SA INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION

		As of June 30 2022	, As of Dec. 3 2021	
n-current assets 27,954 25,637 angible assets 32,550 39,974 apperty, plant and equipment 916 1,023 current financial assets 158 237 al non-current assets 61,578 66,871 rent assets 1,992 1,086 vermment grants receivables 1,055 377 appryments 2,766 2,853 sh and cash equivalents 31,644 41,970 al current assets 99,241 114,600 are premium 33,643 47,738 TAL ASSETS 99,241 114,600 ued capital 3,2,23 43,138 are premium 536,115 536,203 mulative translation adjustement 7,688 5,953 asury shares (893) (847) current labilities 7,538 9,236 n-current liabilities 7,538 9,236 nactire translation adjustement 7,538 9,236 n-current liabilities 7,538 9,236		(in thou	sands of €)	
bodwill 27,954 25,637 angible assets 32,550 39,974 operty, plant and equipment 916 1,023 un-current financial assets 61,578 66,871 tait non-current assets 61,578 66,871 trrent assets 1,992 1,086 overment grants receivables 1,056 1,452 her current assets 205 377 epayments 2,766 2,853 sh and cash equivalents 31,644 41,970 tal current assets 37,663 47,738 TAL ASSETS 99,241 114,609 XUITY AND LIABILITIES taid carrent assets 536,200 mulder's equity 43,223 43,138 are premium 536,115 536,200 mulder befoit (525,431) (508,892) current financial liabilities 7,558 5,953 asaury shares (893) (847) cumulated deficit (526,431) (508,892) tal fourtent financial liabilities 7,538	SETS			
tangible assets 32,550 39,974 operty, plant and equipment 916 1,023 on-current financial assets 158 237 otal non-current assets 61,578 66,871 urrent assets 1,992 1,086 overnment grants receivables 1,056 1,452 ther current assets 205 377 repayments 2,766 2,853 ash and cash equivalents 31,644 41,970 otal current assets 37,663 47,738 DTAL ASSETS 99,241 114,609 QUITY AND LIABILITIES sate aprentime 536,115 536,200 urrent topical 43,223 43,138 fare prentime 536,115 536,200 urrulative translation adjustement 7,688 5,953 (647) (6893) (647) scal Equity 60,702 75,582 9,236 (578 661 on-current liabilities 2,738 9,236 31,067 28,846 31,057 stal Equity 763 <	on-current assets			
Toperty, plant and equipment 916 1,023 on-current financial assets 158 237 otal non-current assets 61,578 66,871 urrent assets 1,992 1,086 urrent assets 1,056 1,452 ther current assets 205 377 repayments 2,766 2,853 ash and cash equivalents 31,644 41,970 otal current assets 37,663 47,738 OTAL ASSETS 99,241 114,609 OUITY AND LIABILITIES 114,609 143,223 hare holder's equity 536,115 536,233 unulative translation adjustement 7,688 5,953 reasury shares (893) (847) ccumulated deficit (525,431) (508,892) on-current financial liabilities 7,538 9,236 on current provisions 578 661 otal non-current liabilities 763 346 on current liabilities 763 346 on current liabilities 763 <td>oodwill</td> <td>27,954</td> <td>25,637</td>	oodwill	27,954	25,637	
Inn-current financial assets 158 237 otal non-current assets 61,578 66,871 turrent assets 1,992 1,086 bovernment grants receivables 1,056 1,452 ther current assets 205 377 trepayments 2,766 2,853 ash and cash equivalents 31,644 41,970 otal current assets 37,663 47,738 OTAL ASSETS 99,241 114,600 QUITY AND LIABILITIES 205 377 issued capital 43,223 43,138 hare premium 536,115 536,203 QUITY AND LIABILITIES 2053 (647) ccurundiated deficit (525,431) (508,892) otal Equity 60,702 75,552 on-current liabilities 20,730 21,160 parternt tiabilities 578 661 otal non-current liabilities 578 661 otal anon-current liabilities 763 346 otal non-current liabilities 763 3	ntangible assets	32,550	39,974	
fotal non-current assets 61,578 66,871 Current assets 1,992 1,086 Sovermment grants receivables 1,056 1,452 Dther current assets 205 377 Prepayments 2,766 2,853 2ash and cash equivalents 31,644 41,970 Total current assets 37,663 47,738 TOTAL ASSETS 99,241 114,609 GUITY AND LIABILITIES 536,115 536,200 Share premium 536,115 536,200 Currunt assets (893) (847) Accurrulative translation adjustement 7,688 5,953 Treasury shares (893) (847) Accurrunt liabilities (525,431) (508,892) Ortal Equity 60,702 75,552 Aon-current liabilities 7,538 9,236 Aon current provisions 578 661 Otal non-current liabilities 763 346 Apyables 4,097 3,649 Deferred tax liabilities 763 <td< td=""><td>Property, plant and equipment</td><td>916</td><td>1,023</td></td<>	Property, plant and equipment	916	1,023	
Current assets 1,992 1,086 Dilents 1,056 1,452 Divernment grants receivables 205 377 Prepayments 2,766 2,853 2ash and cash equivalents 31,644 41,970 Total current assets 37,663 47,738 TOTAL ASSETS 99,241 114,609 EQUITY AND LIABILITIES 31,643 43,223 Share premium 536,115 536,200 Jumulative translation adjustement 7,688 5,953 Treasury shares (893) (847) Accumulated deficit (525,431) (508,892) Total Equity 60,702 75,552 Kon-current liabilities 20,730 21,160 Deferred tax liabilities 2,786 3,461 Non current provisions 578 661 Cotal non-current liabilities 763 3,46 Non current provisions 578 661 Cotal non-current liabilities 763 3,46 Trade payables 4,097 3,	Non-current financial assets	158	237	
Clients 1,992 1,086 Sovernment grants receivables 1,056 1,452 Other current assets 205 377 Prepayments 2,766 2,853 Scash and cash equivalents 31,644 41,970 Yotal current assets 37,663 47,738 YOTAL ASSETS 99,241 114,609 YOULTY AND LIABILITIES 31,641 43,223 Scharcholder's equity 43,223 43,138 Schare premium 536,115 536,200 Yumulative translation adjustement 7,688 5,953 Yeasury shares (893) (847) uccumulated deficit (525,431) (508,892) Yotal Equity 60,702 75,552 Ion-current liabilities 7,538 9,236 Ion-current financial liabilities 7,538 9,236 Ion current provisions 578 661 Yotal non-current liabilities 763 346 Yotal non-current liabilities 763 346 Yotal non-current liabilities 763 346 Yotal non-current liabilities <td< td=""><td>otal non-current assets</td><td>61,578</td><td>66,871</td></td<>	otal non-current assets	61,578	66,871	
Bovernment grants receivables 1,056 1,452 Other current assets 205 377 Prepayments 2,766 2,853 Bash and cash equivalents 31,644 41,970 Otal current assets 37,663 47,738 OTAL ASSETS 99,241 114,609 PQUITY AND LIABILITIES ************************************	Current assets			
205 377 Prepayments 2,766 2,853 Cash and cash equivalents 31,644 41,970 Ordal current assets 37,663 47,738 OTAL ASSETS 99,241 114,609 CQUITY AND LIABILITIES 536,115 536,200 Shareholder's equity 536,115 536,200 Cumulative translation adjustement 7,688 5,953 Treasury shares (893) (847) Accumulated deficit (525,431) (508,892) Total Equity 60,702 75,552 Non-current liabilities 7,538 9,236 Non current provisions 578 661 Otal non-current liabilities 7,538 9,236 Varrent liabilities 7,538 9,236 Varrent liabilities 7,63 346 Trade payables 4,097 3,649 Varrent liabilities 2,886 2,035 Otal non-current liabilities 2,886 2,035 Otal current liabilities 2,886 2,035	Clients	1,992	1,086	
Prepayments 2,766 2,853 Cash and cash equivalents 31,644 41,970 Total current assets 37,663 47,738 TOTAL ASSETS 99,241 114,609 EQUITY AND LIABILITIES 99,241 114,609 Shareholder's equity 43,223 43,138 Share premium 536,115 536,200 Cumulative translation adjustement 7,688 5,953 Treasury shares (893) (847) Accumulated deficit (525,431) (508,892) Total Equity 60,702 75,552 Non-current financial liabilities 7,538 9,236 Non-current financial liabilities 20,730 21,160 Deferred tax liabilities 7,538 9,236 Non current provisions 578 661 Total non-current liabilities 763 346 Trade p	Government grants receivables	1,056	1,452	
Cash and cash equivalents 31,644 41,970 Total current assets 37,663 47,738 TOTAL ASSETS 99,241 114,609 EQUITY AND LIABILITIES 33,643 43,223 43,138 Shareholder's equity 43,223 43,138 536,115 536,200 Cumulative translation adjustement 7,688 5,953 537 Treasury shares (893) (847) Accumulated deficit (525,431) (508,892) Total Equity 60,702 75,552 Non-current financial liabilities 20,730 21,160 Deferred tax liabilities 7,538 9,236 Non current provisions 578 661 Total non-current liabilities 28,846 31,057 Current liabilities 763 346 Trade payables 4,097 3,649 Deferred income 1,947 1,970 Deferred income 1,947 1,970 Deferred income 2,886 2,035 Total current liabilities 2,886 <td>Other current assets</td> <td>205</td> <td>377</td>	Other current assets	205	377	
Total current assets 37,663 47,738 TOTAL ASSETS 99,241 114,609 EQUITY AND LIABILITIES 337,663 47,738 Shareholder's equity 43,223 43,138 Share premium 536,115 536,200 Cumulative translation adjustement 7,688 5,953 Treasury shares (893) (847) Accumulated deficit (525,431) (508,892) Fotal Equity 60,702 75,552 Non-current liabilities 20,730 21,160 Deferred tax liabilities 7,538 9,236 Non current provisions 5778 661 Total non-current liabilities 28,846 31,057 Current liabilities 763 346 Trade payables 4,097 3,649 Deferred income 1,947 1,970 Deferred income 2,886 2,035 Total current liabilities 2,886 2,035	Prepayments	2,766	2,853	
TOTAL ASSETS 99,241 114,609 EQUITY AND LIABILITIES 114,609 114,609 Shareholder's equity 114,609 114,609 ssued capital 43,223 43,138 Share premium 536,115 536,200 Cumulative translation adjustement 7,688 5,953 Treasury shares (893) (847) Accumulated deficit (525,431) (508,892) Total Equity 60,702 75,552 Non-current liabilities 20,730 21,160 Deferred tax liabilities 20,730 21,160 Deferred tax liabilities 7,538 9,236 Non current provisions 578 661 Total non-current liabilities 28,846 31,057 Current liabilities 763 346 Trade payables 4,097 3,649 Deferred income 1,947 1,970 Other current liabilities 2,886 2,035 Total current liabilities 2,886 2,035 Total current liabilities <t< td=""><td>Cash and cash equivalents</td><td>31,644</td><td>41,970</td></t<>	Cash and cash equivalents	31,644	41,970	
Equity AND LIABILITIES Endition Endition Shareholder's equity 43,223 43,138 Share premium 536,115 536,200 Cumulative translation adjustement 7,688 5,953 Treasury shares (893) (847) Accumulated deficit (525,431) (508,892) Fotal Equity 60,702 75,552 Non-current liabilities 20,730 21,160 Deferred tax liabilities 20,730 21,160 Deferred tax liabilities 7,638 9,236 Non current provisions 578 661 Fotal non-current liabilities 28,846 31,057 Current financial liabilities 763 346 Trade payables 763 346 Current financial liabilities 763 346 Current liabilities 763 346 Current financial liabilities 763 346 Current financial liabilities 763 346 Current financial liabilities 763 346 Curent financia	Fotal current assets	37,663	47,738	
Shareholder's equity 43,223 43,138 Share premium 536,115 536,200 Cumulative translation adjustement 7,688 5,953 Treasury shares (893) (847) Accumulated deficit (525,431) (508,892) Fotal Equity 60,702 75,552 Non-current liabilities 20,730 21,160 Deferred tax liabilities 7,538 9,236 Non current provisions 578 661 Fotal non-current liabilities 28,846 31,057 Current financial liabilities 763 346 Frade payables 763 346 Frade payables 4,097 3,649 Deferred income 1,947 1,970 Deter current liabilities 2,886 2,035 Fotal current liabilities 2,886 2,035	TOTAL ASSETS	99,241	114,609	
ssued capital 43,223 43,138 Share premium 536,115 536,200 Cumulative translation adjustement 7,688 5,953 Freasury shares (893) (847) Accumulated deficit (525,431) (508,892) Freasury shares 60,702 75,552 Non-current liabilities 20,730 21,160 Opeferred tax liabilities 7,538 9,236 Non current provisions 578 661 Fotal non-current liabilities 7,633 346 Current liabilities 763 346 Current liabilities 763 346 Current liabilities 763 346 Current liabilities 763 346 Frade payables 4,097 3,649 Opeferred income 1,947 1,970 Other current liabilities 2,886 2,035 Fotal current liabilities 9,693 8,000	EQUITY AND LIABILITIES			
Share premium 536,115 536,200 Cumulative translation adjustement 7,688 5,953 Treasury shares (893) (847) Accumulated deficit (525,431) (508,892) Total Equity 60,702 75,552 Non-current liabilities 20,730 21,160 Deferred tax liabilities 7,538 9,236 Non current provisions 578 661 Total non-current liabilities 7,538 9,236 Non current provisions 578 661 Total non-current liabilities 7,633 346 Current liabilities 763 346 Current liabilities 763 346 Current liabilities 2,886 2,035 Current liabilities 2,886 2,035 Fotal none 1,947 1,970 Deferred income 2,886 2,035 Total current liabilities 9,693 8,000	Shareholder's equity			
Cumulative translation adjustement 7,688 5,953 Treasury shares (893) (847) Accumulated deficit (525,431) (508,892) Total Equity 60,702 75,552 Non-current liabilities 20,730 21,160 Deferred tax liabilities 7,538 9,236 Non current provisions 5778 661 Total non-current liabilities 28,846 31,057 Current liabilities 763 346 Trade payables 4,097 3,649 Deferred income 1,947 1,970 Current liabilities 2,886 2,035 Trade payables 2,886 2,035 Total current liabilities 2,886 2,035	ssued capital	43,223	43,138	
Treasury shares (893) (847) Accumulated deficit (525,431) (508,892) Total Equity 60,702 75,552 Non-current liabilities 20,730 21,160 Deferred tax liabilities 7,538 9,236 Non current provisions 578 661 Total non-current liabilities 578 661 Current financial liabilities 346 31,057 Current financial liabilities 763 346 Trade payables 4,097 3,649 Deferred income 1,947 1,970 Deferred liabilities 2,886 2,035 Total current liabilities 9,693 8,000	Share premium	536,115	536,200	
Accumulated deficit (525,431) (508,892) Fotal Equity 60,702 75,552 Non-current liabilities 20,730 21,160 Deferred tax liabilities 7,538 9,236 Non current provisions 578 661 Total non-current liabilities 28,846 31,057 Current liabilities 763 346 Current liabilities 763 3649 Deferred income 1,947 1,970 Other current liabilities 2,886 2,035 Total current liabilities 9,693 8,000	Cumulative translation adjustement	7,688	5,953	
Fotal Equity 60,702 75,552 Non-current liabilities 20,730 21,160 Deferred tax liabilities 7,538 9,236 Non current provisions 578 661 Total non-current liabilities 28,846 31,057 Current liabilities 28,846 31,057 Current liabilities 763 346 Trade payables 4,097 3,649 Deferred income 1,947 1,970 Dther current liabilities 2,886 2,035 Total current liabilities 9,693 8,000	Treasury shares	(893)	(847)	
Non-current liabilities20,73021,160Deferred tax liabilities7,5389,236Non current provisions578661Total non-current liabilities28,84631,057Current liabilities763346Current financial liabilities763346Current financial liabilities1,9473,649Deferred income1,9471,970Other current liabilities2,8862,035Total current liabilities9,6938,000	Accumulated deficit	(525,431)	(508,892)	
Non-current financial liabilities20,73021,160Deferred tax liabilities7,5389,236Non current provisions578661Total non-current liabilities28,84631,057Current liabilities763346Current financial liabilities763346Current financial liabilities1,9473,649Deferred income1,9471,970Other current liabilities2,8862,035Total current liabilities9,6938,000	Fotal Equity	60,702	75,552	
Deferred tax liabilities7,5389,236Non current provisions578661Total non-current liabilities28,84631,057Current liabilities763346Current financial liabilities763346Trade payables4,0973,649Deferred income1,9471,970Other current liabilities2,8862,035Total current liabilities9,6938,000	Non-current liabilities			
Non current provisions578661Total non-current liabilities28,84631,057Current liabilities763346Current financial liabilities763346Current financial liabilities763346Current financial liabilities763346Current financial liabilities763346Current financial liabilities763346Current financial liabilities763346Current liabilities2,8862,035Cotal current liabilities9,6938,000	Non-current financial liabilities	20,730	21,160	
Fotal non-current liabilities28,84631,057Current liabilities763346Current financial liabilities763346Frade payables4,0973,649Deferred income1,9471,970Other current liabilities2,8862,035Fotal current liabilities9,6938,000	Deferred tax liabilities	7,538	9,236	
Current liabilities763346Current financial liabilities763346Frade payables4,0973,649Deferred income1,9471,970Dther current liabilities2,8862,035Total current liabilities9,6938,000	Non current provisions	578	661	
Current financial liabilities763346Trade payables4,0973,649Deferred income1,9471,970Other current liabilities2,8862,035Total current liabilities9,6938,000	Total non-current liabilities	28,846	31,057	
Trade payables 4,097 3,649 Deferred income 1,947 1,970 Other current liabilities 2,886 2,035 Total current liabilities 9,693 8,000	Current liabilities			
Deferred income1,9471,970Dther current liabilities2,8862,035Total current liabilities9,6938,000	Current financial liabilities	763	346	
Other current liabilities 2,886 2,035 Total current liabilities 9,693 8,000	Frade payables	4,097	3,649	
Fotal current liabilities 9,693 8,000	Deferred income	1,947	1,970	
	Other current liabilities	2,886	2,035	
OTAL LIABILITIES AND EQUITY 99.241 114.609	Fotal current liabilities	9,693	8,000	
	OTAL LIABILITIES AND EQUITY	99.241	114.609	